A Practical Approach to Pharmaceutical Policy Andreas Seiter June 2010 by World Bank ISBN: 0-8213-8386-8 ISBN-13: 978-0-8213-8386-5 SKU: 18386 Book [240p] available online at: http://bit.ly/aROO8L “………..Pharmaceuticals are an essential component of health care. But for many people in low- and middle-income countries, access to the medicines they need to prevent or treat severe illnesses is limited. Typical problems are lack of availability, costs that exceed the individual’s purchasing power or lack of competent “agents” – health workers that are well trained to give the correct advice on which medicines to take. Pharmaceutical policy is the part of health policy that aims at addressing these problems and increasing access to safe, effective and affordable medicines for all patients. There are many obstacles against achieving these goals. Such obstacles can arise from financial interests on the side of suppliers and health care providers, who may benefit from charging higher prices and issuing more prescriptions than might be justified from a clinical and economic viewpoint. Or from rogue suppliers trying to introduce low quality or counterfeit drugs into markets with less effective regulation. Also, corruption and ineffective bureaucracies sometimes interfere with well intended programs to offer access to essential medicines for the poor. This book offers policy makers a hands-on approach, tested in the World Bank’s field work in many countries, for assessing the pharmaceutical sector, recognizing typical “patterns of dysfunction” and developing strategies to quickly deal with the most urgent problems while at the same time building a platform for sustainable long term policy. It offers examples from a variety of low- and middle income countries and provides practical assessment tools for policy makers. The book ends with the author’s outlook on future developments in this complex policy field…………” TABLE OF CONTENTS Chapter 1. Pharmaceutical Policy Goals Pharmaceutical Policy Framework • Parameters for Monitoring the Effect and Progress of Pharmaceutical Reforms Chapter 2. Introducing the Stakeholders Multinational Research-Based Companies • Multinational Generics Companies • National Generics Companies • Brokers • Procurement Agents • Importers and Agents • Wholesalers • Central Medical Stores • Retail Pharmacists and Drug Sellers • Prescribers • Consumers • Public Policy Makers: Legislative and Executive • Regulatory and Executive Agencies • Expert Commissions and Advisers • Civil Society Organizations • International Agencies and Donors • Public Purchasers • Payers • Pharmaceutical Benefit Managers • Consultants Chapter 3. Patterns of Dysfunction Inadequate Regulation of Core Pharmaceutical Sector Functions • Lack or Misuse of Funds • Ineffective or Inefficient Procurement • Dysfunctional Supply Chains • Corruption, Abuse of Public Funds, and Unethical Business Practices • Inadequate Incentives for Providers and Policy Makers • Medicine Prices Perceived as Too High • Conflicts between Innovation and Cost Containment • Conflicts between Industrial Policy and Public Health Objectives • Irrational or Inappropriate Use of Drugs • A Tool to Assess the Sector and Diagnose Dysfunctions Chapter 4. Key Elements of a Successful Pharmaceutical Policy Ensuring Access to Safe and Effective Drugs through Well-Designed Supply Chains • Using Purchasing Power to Get Value for Money • Managing the Decision Process on Formulary Inclusion • Creating Adequate Information Systems • Ensuring Rational and Cost-Effective Use of Medicines • Securing Adequate Financing and Payment Mechanism for Pharmaceuticals • Reconciling Health Policy and Industrial Policy in the Pharmaceutical Sector • Ensuring Good Governance of the Sector Chapter 5. Policy Packages to Achieve Strategic Long-Term Goals Essential Medicines Policy • Generic Drugs Policy • Innovation-Friendly Drugs Policy • Combining Several Policy Models within One Country Chapter 6. Factors Influencing Policy Implementation Stakeholder Assessment and Involvement • Strategies to Neutralize Political Opposition Chapter 7. Pharmaceutical Policy Illustrated in Country Examples Ghana: National Health Insurance as a A?Game ChangerA? • Lithuania: Dealing with the Effects of the Financial Crisis • China: Improving Social Protection for the Rural Poor • Russian Federation: Affordability and Access to Essential Drugs • Liberia: Building Up after Conflict Chapter 8. Pharmaceutical Policy Outlook Regulatory Framework • Drug Prices • Financing and Management of Drug Benefits • Effect on Markets and Industry • General Trend: Convergence toward Models That Work http://issuu.com/world.bank.publications/docs/9780821383865/1?zoomed=&zoomPercent=&zoomX=&zoomY=&noteText=&noteX=&not ewMode=magazine * * * This message from the Pan American Health Organization, PAHO/WHO, is part of an effort to disseminate information Related to: Equity; Health inequality; Socioeconomic inequality in health; Socioeconomic health differentials; Gender; Violence; Poverty; Health Economics; Health Legislation; Ethnicity; Ethics; Information Technology - Virtual libraries; Research & Science issues. [DD/ KMC Area] “Materials provided in this electronic list are provided "as is". Unless expressly stated otherwise, the findings and interpretations included in the Materials are those of the authors and not necessarily of The Pan American Health Organization PAHO/WHO or its country members”. ------------------------------------------------------------------------------------ PAHO/WHO Website Equity List - Archives - Join/remove: http://listserv.paho.org/Archives/equidad.html Twitter http://twitter.com/eqpaho IMPORTANT: This transmission is for use by the intended recipient and it may contain privileged, proprietary or confidential information. If you are not the intended recipient or a person responsible for delivering this transmission to the intended recipient, you may not disclose, copy or distribute this transmission or take any action in reliance on it. If you received this transmission in error, please dispose of and delete this transmission. Thank you. .